PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
Open Access
- 15 July 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11518
Abstract
Cyclic nucleotide phosphodiesterases 4 (PDE4) are a family of enzymes which specifically promote the hydrolysis and degradation of cAMP. The inhibition of PDE4 enzymes has been widely investigated as a possible alternative strategy for the treatment of a variety of respiratory diseases, including chronic obstructive pulmonary disease and asthma, as well as psoriasis and other autoimmune disorders. In this context, the identification of new molecules as PDE4 inhibitors continues to be an active field of investigation within drug discovery. This review summarizes the medicinal chemistry journey in the design and development of effective PDE4 inhibitors, analyzed through chemical classes and taking into consideration structural aspects and binding properties, as well as inhibitory efficacy, PDE4 selectivity and the potential as therapeutic agents.Keywords
This publication has 100 references indexed in Scilit:
- Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal centerFEBS Letters, 2012
- Discovery of oxazole-based PDE4 inhibitors with picomolar potencyBioorganic & Medicinal Chemistry Letters, 2012
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBritish Journal of Pharmacology, 2011
- Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological FunctionsPhysiological Reviews, 2011
- Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological diseaseExpert Opinion on Pharmacotherapy, 2009
- Dual Inhibitors of Phosphodiesterase-4 and Serotonin ReuptakeJournal of Medicinal Chemistry, 2009
- Keynote review: Phosphodiesterase-4 as a therapeutic targetDrug Discovery Today, 2005
- Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding siteBioorganic & Medicinal Chemistry Letters, 1995